FK866 (APO866): NAMPT Inhibitor Targeting Cancer Metabolism

Executive Summary: FK866 (APO866) is a potent, non-competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in NAD biosynthesis (APExBIO). It exhibits nanomolar inhibitory activity (Ki = 0.4 nM; IC50 range: 0.09–27.2 nM) and selectively induces caspase-independent cell death in acute myeloid leukemia (AML) cells, sparing normal progenitors (Ji et al., 2025). FK866 depletes intracellular NAD and ATP, triggers mitochondrial depolarization, and induces autophagy dependent on protein synthesis. It demonstrates significant antitumor efficacy in vivo, including improved survival in mouse xenograft models. FK866 is supplied as a solid compound by APExBIO (SKU: A4381) for advanced hematologic cancer and metabolism research (product page).

Biological Rationale

Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step in the salvage pathway of NAD biosynthesis. NAD is essential for cellular metabolism, DNA repair, and cell survival. In malignancies such as AML, cancer cells exhibit increased dependence on NAMPT-mediated NAD production to sustain rapid proliferation and resist apoptosis (Ji et al., 2025). Selective targeting of NAMPT disrupts NAD homeostasis, leading to energy failure and cell death in cancer cells while minimizing toxicity to normal hematopoietic progenitors. FK866 (APO866) exploits this metabolic vulnerability, establishing a mechanistic foundation for therapeutic intervention in hematologic cancers. The biological rationale is reinforced by experimental evidence showing that NAMPT inhibition abrogates DNA repair and stress adaptation, especially in rapidly dividing malignant cells (Related Article 1).

Mechanism of Action of FK866 (APO866)

FK866 (APO866) is a highly specific, non-competitive NAMPT inhibitor. It binds to NAMPT with a Ki of 0.4 nM and exhibits IC50 values from 0.09 nM to 27.2 nM, depending on cell type and assay conditions (Ji et al., 2025). Inhibition of NAMPT blocks the conversion of nicotinamide to nicotinamide mononucleotide (NMN), thereby preventing NAD synthesis via the salvage pathway. Depletion of intracellular NAD leads to rapid ATP loss, mitochondrial membrane depolarization, and disruption of energy-dependent processes. FK866 induces cell death through a caspase-independent pathway, involving mitochondrial dysfunction and autophagy dependent on de novo protein synthesis. Importantly, normal hematopoietic progenitor cells are relatively spared due to lower NAMPT dependence, highlighting the compound’s selectivity for cancer metabolism targeting (Related Article 2 contrasts with this article by focusing on selectivity across hematologic models).

Evidence & Benchmarks

• FK866 inhibits NAMPT activity with a Ki of 0.4 nM, as determined by enzymatic assays (Ji et al., 2025).
• IC50 values for FK866 in cellular models range from 0.09 nM to 27.2 nM, depending on cell line and context (Ji et al., 2025).
• FK866 causes rapid NAD and ATP depletion in AML cells, leading to selective cytotoxicity, while normal progenitor cells remain largely unaffected (Ji et al., 2025).
• Caspase-independent cell death and mitochondrial membrane depolarization are observed following FK866 treatment in vitro and in vivo (Ji et al., 2025).
• Significant antitumor efficacy and survival benefit are demonstrated in mouse xenograft models of AML and lymphoblastic lymphoma treated with FK866 (Ji et al., 2025).
• FK866-induced autophagy requires de novo protein synthesis, as shown by cycloheximide inhibition assays (Ji et al., 2025).
• Inhibitors of NAMPT, such as FK866, block the beneficial role of NAD+ elevation in vascular smooth muscle cell senescence, confirming target engagement (Ji et al., 2025).

This article extends the mechanistic insights from FK866 (APO866): NAMPT Inhibitor Applications in Cancer and Aging by providing updated, DOI-anchored in vivo efficacy data and clarifying autophagy dependencies.

Applications, Limits & Misconceptions

FK866 (APO866) is widely used in:

• Hematologic cancer research, especially for dissecting AML metabolism and cell death mechanisms.
• Cancer metabolism studies, targeting NAD biosynthesis pathways.
• Preclinical antitumor efficacy evaluation in xenograft mouse models.
• Cellular stress and autophagy pathway interrogation, including mitochondrial function and energy regulation.
• Vascular aging and DNA damage research, as a tool to interrogate NAMPT’s role in non-malignant cells (Ji et al., 2025).

Common Pitfalls or Misconceptions

• FK866 is not a pan-cytotoxic agent: It exhibits selective cytotoxicity, primarily affecting cells highly dependent on NAMPT-mediated NAD salvage (e.g., AML cells).
• Not suitable for use in water-based buffers: FK866 is insoluble in water; dissolve in DMSO (≥19.6 mg/mL) or ethanol (≥49.6 mg/mL) for experimental use (APExBIO).
• Does not induce apoptosis via caspase activation: Cell death induced by FK866 is caspase-independent, involving mitochondrial depolarization and autophagy.
• Not universally effective in all cancer types: Efficacy depends on NAMPT expression and NAD salvage reliance; some solid tumors may show resistance.
• Stock solutions stability: Solutions are stable below -20°C for several months but recommended for short-term use only (APExBIO).

Workflow Integration & Parameters

FK866 (APO866) is supplied as a solid (chemical name: (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide; molecular formula: C24H29N3O2) by APExBIO (SKU: A4381). For experimental use:

• Solubility: Dissolve in DMSO (≥19.6 mg/mL) or ethanol (≥49.6 mg/mL).
• Storage: Store solid at -20°C; stock solutions below -20°C for up to several months.
• Recommended concentrations: Nanomolar range (e.g., 0.1–100 nM) depending on cell model and application.
• Controls: Use vehicle-only (DMSO or ethanol) controls in all experiments.
• Workflow tips: Prepare fresh working solutions; avoid repeated freeze-thaw cycles. See FK866 (APO866): Redefining NAMPT Inhibition for Precision for advanced troubleshooting and protocol customization. This article updates that resource with new storage and stability data.

Conclusion & Outlook

FK866 (APO866) is a reference NAMPT inhibitor for hematologic cancer and metabolism research, enabling selective NAD/ATP depletion and targeted cell death via non-apoptotic pathways. Its nanomolar potency, high specificity, and robust in vivo efficacy make it a cornerstone for both basic and translational studies in cancer metabolism and vascular aging. The compound’s precise workflow requirements and selectivity profile should be carefully considered to maximize reproducibility and biological insight. For detailed specifications or to order, see the FK866 (APO866) product page. Ongoing research is expanding its use in translational models of aging and stress adaptation (Ji et al., 2025).